As Henry I. Miller and Gregory Conko recently pointed out, the Second Circuit Court of Appeals in 2012 overturned the conviction of a pharmaceutical sales representative who told a doctor about off-label uses of Xyrem, a prescription drug manufactured by Orphan Medical, Inc. 

New Health and Human Services Secretary Alex Azar has identified his main priorities. At the top of his list is lowering prescription drug prices.

Contrary to the prevailing narrative, health care reform is alive and progressing. The public only hears about a bungling Congress that cannot repeal and replace the Affordable Care Act, a law that is already imploding on its own. This administration continues to implement strategic deregulation that will lower the cost of medical care and insurance through competition.